Trade

with

Anacor Pharmaceuticals Inc
(NASDAQ: ANAC)
AdChoices
28.40
+0.14
+0.50%
Pre-Market :
28.33
-0.07
-0.25%

Open

28.17

Previous Close

28.26

Volume (Avg)

11.70k (558.10k)

Day's Range

28.02-28.40

52Wk Range

11.34-28.73

Market Cap.

1.19B

Dividend Rate ( Yield )

-

Beta

1.89

Shares Outstanding

42.00M

P/E Ratio (EPS)

17.57 (1.61)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 17.23M

    • Net Income

    • 84.76M

    • Market Cap.

    • 1.19B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 355.79

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.89

    • Forward P/E

    • -12.50

    • Price/Sales

    • 62.50

    • Price/Book Value

    • 14.03

    • Price/Cash flow

    • 15.41

      • EBITDA

      • 91.03M

      • Return on Capital %

      • 70.15

      • Return on Equity %

      • 156.72

      • Return on Assets %

      • 70.15

      • Book Value/Share

      • 2.02

      • Shares Outstanding

      • 42.00M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 32.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -2.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -14.40

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -7.23

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • 364.69

            • 39.38

            • Net Profit Margin

            • 355.79

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -85.20

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -87.10

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.28

              • 0.76

              • Current Ratio

              • 5.75

              • 2.92

              • Quick Ratio

              • 5.63

              • 2.35

              • Interest Coverage

              • 16.81

              • 38.02

              • Leverage Ratio

              • 1.63

              • 2.21

              • Book Value/Share

              • 2.02

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 17.57

                • 243.90

                • P/E Ratio 5-Year High

                • 17.70

                • 634.30

                • P/E Ratio 5-Year Low

                • 1.87

                • 124.82

                • Price/Sales Ratio

                • 62.50

                • 9.29

                • Price/Book Value

                • 14.01

                • 8.39

                • Price/Cash Flow Ratio

                • 15.41

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 156.72

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 70.15

                    (-37.10)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 101.46

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 864.04k

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.20

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  92.52M
                  Operating Margin
                  537.02
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  15.41
                  Ownership

                  Institutional Ownership

                  94.96%

                  Top 10 Institutions

                  48.57%

                  Mutual Fund Ownership

                  30.29%

                  Float

                  78.59%

                  5% / Insider Ownership

                  2.65%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Eagle Small Cap Growth Fund

                  •  

                    1,258,892

                  • 2.44

                  • 3.00

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    903,303

                  • 0.00

                  • 2.15

                  • SPDR® S&P Biotech ETF

                  •  

                    645,064

                  • -9.84

                  • 1.74

                  • Oppenheimer Global Opportunities

                  •  

                    600,000

                  • 315.46

                  • 1.43

                  • iShares Nasdaq Biotechnology

                  •  

                    545,853

                  • -0.24

                  • 1.47

                  • Vanguard Total Stock Mkt Idx

                  •  

                    529,145

                  • 2.55

                  • 1.26

                  • iShares Russell 2000 (AU)

                  •  

                    499,159

                  • -1.81

                  • 1.34

                  • Loomis Sayles Small Cap Growth Fund

                  •  

                    408,061

                  • -2.47

                  • 0.97

                  • Vanguard Extended Market Index Fund

                  •  

                    394,238

                  • 33.62

                  • 0.94

                  • Hartford Healthcare Fund

                  •  

                    384,900

                  • 0.00

                  • 0.92

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Wellington Management Company, LLP

                  •  

                    3,397,773

                  • -2.94%

                  • 8.11

                  • Baker Bros Advisors LLC

                  •  

                    3,248,043

                  • +4.93%

                  • 7.75

                  • GlaxoSmithKline PLC

                  •  

                    2,771,374

                  • 0.00%

                  • 6.62

                  • Eagle Asset Management, Inc.

                  •  

                    1,973,348

                  • +40.49%

                  • 4.70

                  • Palo Alto Investors, LLC

                  •  

                    1,661,612

                  • -47.15%

                  • 3.96

                  • Westfield Capital Management Company, LP

                  •  

                    1,659,070

                  • +45.72%

                  • 3.96

                  • VHCP Management, LLC

                  •  

                    1,545,999

                  • 0.00%

                  • 3.69

                  • Broadfin Capital, LLC

                  •  

                    1,443,220

                  • +44.20%

                  • 3.44

                  • Kingdon Capital Management LLC

                  •  

                    1,355,847

                  • +11.18%

                  • 3.23

                  • BlackRock Fund Advisors

                  •  

                    1,304,235

                  • +8.31%

                  • 3.11

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Core

                  Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule thera...morepeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company’s main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of peo...moreple. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.lessless

                  Key People

                  Mr. Paul L. Berns

                  Chairman of the Board/Director/President/CEO

                  Dr. Lucy Shapiro PhD

                  Co-Founder/Director

                  Mr. Geoffrey M. Parker

                  CFO/Chief Accounting Officer/Executive VP

                  Vincent Ippolito

                  Executive VP/Other Executive Officer

                  Keith R. Leonard

                  Director

                  • Anacor Pharmaceuticals Inc

                  • 1020 East Meadow Circle

                  • Palo Alto, CA 94303-4230

                  • USA.Map

                  • Phone: +1 650 543-7500

                  • Fax: +1 650 543-7660

                  • anacor.com

                  Incorporated

                  2000

                  Employees

                  79

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: